These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33279901)

  • 1. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.
    Jacobi O; Ross JS; Goshen-Lago T; Haddad R; Moore A; Sulkes A; Brenner B; Ben-Aharon I
    Oncol Res Treat; 2021; 44(1-2):20-27. PubMed ID: 33279901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX4 is associated with poor prognosis in cholangiocarcinoma.
    Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
    Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of EGFR family gene aberrations in cholangiocarcinoma.
    Yang X; Wang W; Wang C; Wang L; Yang M; Qi M; Su H; Sun X; Liu Z; Zhang J; Qin X; Han B
    Oncol Rep; 2014 Aug; 32(2):700-8. PubMed ID: 24927194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
    Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
    Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study.
    Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing.
    Stenzinger A; Vogel A; Lehmann U; Lamarca A; Hofman P; Terracciano L; Normanno N
    Cancer Treat Rev; 2024 Jan; 122():102649. PubMed ID: 37984132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma.
    Yamada T; Nakanishi Y; Hayashi H; Tanishima S; Mori R; Fujii K; Okamura K; Tsuchikawa T; Nakamura T; Noji T; Asano T; Matsui A; Tanaka K; Watanabe Y; Kurashima Y; Ebihara Y; Murakami S; Shichinohe T; Mitsuhashi T; Hirano S
    HPB (Oxford); 2022 Jul; 24(7):1035-1043. PubMed ID: 34903468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteogenomic characterization of cholangiocarcinoma.
    Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
    Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
    Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
    Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis.
    Albrecht T; Rausch M; Rössler S; Albrecht M; Braun JD; Geissler V; Mehrabi A; Vogel MN; Pathil-Warth A; Mechtersheimer G; Renner M; Rupp C; Weiss KH; Busch E; Köhler B; Springfeld C; Schirmacher P; Goeppert B
    BMC Cancer; 2019 Dec; 19(1):1191. PubMed ID: 31805897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
    Kim ST; Banks KC; Pectasides E; Kim SY; Kim K; Lanman RB; Talasaz A; An J; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Park SH; Park JO; Park YS; Lim HY; Kim NKD; Park W; Lee H; Bass AJ; Kim K; Kang WK; Lee J
    Ann Oncol; 2018 Apr; 29(4):1037-1048. PubMed ID: 29409051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab, not lapatinib, has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma.
    Mou HB; Li WD; Shen YJ; Shi JP; Guo XD; Yao M; Wang K; Zhang T
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):477-479. PubMed ID: 30262418
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.